Sartorius stock
Price history
+27.56% over the period1 year: from €175.60 (November 20, 2025) to €224.00 (November 20, 2026), +27.56%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | €224.00 |
| October 30, 2026 | €229.00 |
| September 30, 2026 | €206.00 |
| August 31, 2026 | €197.60 |
| July 31, 2026 | €177.00 |
| June 30, 2026 | €187.80 |
| May 29, 2026 | €194.60 |
| April 30, 2026 | €174.60 |
| March 31, 2026 | €168.60 |
| February 27, 2026 | €191.40 |
| January 30, 2026 | €189.40 |
| December 30, 2025 | €191.00 |
| November 28, 2025 | €194.80 |
| November 20, 2025 | €175.60 |
At a glance
The company
Provide bioprocess solutions, lab products and analytical systems for life science research, biopharmaceutical manufacturing, and cell and gene therapy
Latest results
Quarter to September 30, 2026 · EPS €1.27 (estimate €1.25)
TickerLandia's take on Sartorius
- Pricier than usual relative to earnings: P/E on the latest fiscal year 100 vs a median of 81 over its last 10 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 71 vs 42 (+69%) in a group of 10.
- Strong point: Market momentum (86/100 in its group). Weak point: Financial strength (15/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−5.68% from the 52-week high
Analysts · 8 analysts
Average target€266.47+18.96% vs. price
Buy 6 · Hold 2 · Sell 0 · Buy
TickerLandia Fingerprint: Sartorius
Compared with similar companies: very strong momentum and very low financial strength.
Financials and price compared with 34 companies in the medical instruments & supplies industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricehigh74
How much it costs relative to what it produces.
Metric Value Position in group Forward P/E 34.1 78 EV/EBITDA 21.6 72 P/E (trailing 12 months) 70.9 85 Price/book 5.71 72 Price/sales 4.22 63 Profitabilityaverage41
How much it earns on revenue and capital.
Metric Value Position in group Net margin 6.0% 34 Gross margin 45.4% 34 Operating margin 17.8% 60 ROE 7.9% 43 ROA 4.2% 37 Earnings stabilityaverage41
How steady its margins were over the last five annual reports.
Metric Value Position in group Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Margin variabilitycounts in reverse: lower means more earnings stability 6.9% 19 Growthlow38
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) −5.37% 4 Revenue growth (year over year) +9.90% 72 Financial strengthvery low15
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Current ratio 1.07 19 Interest coverage 3.30 18 Debt/equitycounts in reverse: lower means more financial strength 0.94 20 Net debt/EBITDAcounts in reverse: lower means more financial strength 4.22 5 Dividendlow38
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 27 years 71 Dividend yield 0.3% 15 Payout ratio 23.1% 27 Market momentumvery strong86
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +17.33% 89 Relative strength (6 months) +20.50% 87 1-year return +27.56% 75 Distance from 200-day average +17.82% 91 Riskaverage56
How much the price swings.
Metric Value Position in group Beta (1 year) 0.98 70 Volatility (60 days) 31.5% 64 Maximum drawdown (12 months) 20.5% 34
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Sartorius is pricier than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Sartorius's P/E today is 99.8, above the median of its last 10 fiscal years (80.8; between 33.7 and 141.6 from 2016 to 2025). Sartorius's P/E (trailing 12 months): 70.9, +69% against the median of a group of 10 similar companies (41.9).
Compared with 10 similar companies
| Metric | Sartorius | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 70.9 | High | |
| Forward P/E | 34.1 | High | |
| Operating margin | 17.8% | Middle | |
| ROE | 7.9% | Middle | |
| Debt/equity | 0.94 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Sartorius. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€926.3M
Latest quarter · Q3 2026
Net income
€66.1M
Latest quarter · Q3 2026
Quarterly net margin
7.1%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- €15.47B
- P/E
- 70.9
- EPS
- €3.16
- Volume
- 3.83K
- Daily trading
- €1.13M
- Dividend yield
- 0.33%
- Last ex-dividend on March 27, 2026
How Sartorius is changing
All resultsRevenue grew 8.7% a year on average over the last 5 years
Operating margin fell from 28.2% to 16.0%
Returns
Sartorius returns with dividends
€1,000 invested in Sartorius 5 years ago, on November 22, 2021, would be worth €451 today with dividends reinvested: −54.87% in total, −14.73% per year. On price alone it would be €443 (−55.73%).
| Period | Sartorius | DAX | €1,000 becomes |
|---|---|---|---|
| 1 month | +7.43% | −1.98% | €1,074 |
| 6 months | +20.82% | +0.26% | €1,208 |
| Year to date | +17.28% | +1.28% | €1,173 |
| 1 year | +28.12% | +6.55% | €1,281 |
| 3 years | +1.36% | +55.98% | €1,014 |
| 5 years | −54.87% | +53.90% | €451 |
| 10 years | +240.22% | +132.12% | €3,402 |
Over the last 6 months it has done better than 52% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. DAX: with dividends. Calculate your investment
The chart in detail
Sartorius: technical analysis
Sartorius is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 72.9% below its all-time closing high (€827.00, September 7, 2021).
- Trend
- Upward
- RSI (14 sessions)
- 51
- Between 30 and 70
- vs 200-session average
- +17.82%
Active signals
The price is moving in an unusually narrow range compared with the last year.
since November 18, 2026
Support and resistance
Price areas where Sartorius has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price€224.00
- Support€215.00−4.02%2 touches, last on October 6, 2026
- Support€207.50−7.37%3 touches, last on January 26, 2026
- Support€202.25−9.71%4 touches, last on September 1, 2026
Volatility and risk
Over the last year it has moved roughly in line with the DAX.
- Beta (1 year) vs DAX
- 0.98
- Volatility (60 sessions, annualised)
- 31.5%
- Largest fall in the last year
- −20.49%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Sartorius: seasonality
Average monthly price change over 28 years
Over the last 28 years, the strongest month for Sartorius has been February: +6.00% on average, positive in 18 years out of 27. The weakest has been September: −3.20% on average, positive in 11 years out of 28. November, the current month, has been positive in 17 years out of 27 (+4.40% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +4.27% | +4.09% | 19 of 27 |
| February | +6.00% | +6.01% | 18 of 27 |
| March | +4.15% | +2.61% | 16 of 27 |
| April | +1.36% | +2.38% | 16 of 27 |
| May | −0.80% | −1.09% | 12 of 28 |
| June | +2.46% | +2.58% | 18 of 28 |
| July | +3.85% | +3.89% | 18 of 28 |
| August | +1.57% | +0.35% | 15 of 28 |
| September | −3.20% | −2.66% | 11 of 28 |
| October | −0.84% | −0.01% | 14 of 28 |
| November | +4.40% | +2.31% | 17 of 27 |
| December | +1.00% | 0.00% | 13 of 27 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Sartorius and its competitors
Pipettes, bioreactors and lab weighing instruments are among the products most often associated with Sartorius in laboratories. The range also covers cell culture media and reagents, filtration and water purification systems, microbiological testing solutions and process chromatography. Its customers include research laboratories, biopharmaceutical manufacturers and companies developing gene therapies, and it sells in markets around the world.
- Headquarters
- Göttingen, Germany
- Employees
- 14,273
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| SartoriusSRT | $17B | 17.8% | 70.9 | +20.82% |
| ColoplastCOLO.B | $16.42B | 25.7% | 36.3 | +20.27% |
| Straumann HoldingSTMN | $20.63B | 24.7% | 47.0 | +21.00% |
| Sartorius Stedim BiotechDIM | $24.45B | 19.2% | 68.6 | +34.68% |
| AlconALC | $35.65B | 12.9% | 57.1 | +17.55% |
| Ypsomed HoldingYPSN | $6.9B | 31.0% | 34.9 | +30.53% |
Same industry or related industries, similar size. Compare Sartorius with its competitors · Full profile
